On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s lead innovative product Epidaza®, an oral subtype-selective histone deacetylase inhibitor, previously approved for recurrent and refractory peripheral T cell lymphoma in China, has received approval for marketing application in its second indication from NMPA.
November 29, 2019
· 4 min read